Treatment of Symptomatic Gastrointestinal Motility Disturbances in Limited Cutaneous Systemic Sclerosis

This protocol addresses the specific management of symptomatic gastrointestinal motility disturbances occurring in the setting of limited cutaneous systemic sclerosis (lcSSc).

Clinical scenario: A patient with limited cutaneous systemic sclerosis (lcSSc) presenting with symptomatic gastrointestinal motility disturbances requiring targeted treatment.

Current evidence supports considering a specific class of drugs acting on gastrointestinal motility for this situation. The complete protocol — including which agents apply, the selection criteria, and the full clinical guidance — is available below.

Instant Access to Structured Evidence-Based Regimens

References

The use of prokinetic drugs should be considered for the treatment of symptomatic motility disturbances related to SSc.

DOI: 10.1136/ard-2024-226430

View source ↗